Baylor University

Oxigene, Inc.

Genmab A+s

Klaus Edvardsen

Kevin G Pinney

David J Chaplin

Joseph Anthony Prezioso

Robert Ronald Kane

Charles Manly Garner, Iii

Zhi Chen

Vani P Mocharla

James Michael Dorsey

Mallinath Hadimani

Paul Parren

Jan Van De Winkel

Ole Baadsgaard

Willem Karel Bleeker

Steen Lisby

Charles M Garner

Anupama Shirali

Jeroen Lammerts Van Bueren

Phyllis Arthasary

Thomas Valerius

Michael Dechant

Raymond Kessler

Usha Ghatak, Legal Representative

Wencke Weisner

Usha R Ghatak, Legal Representative

Sven Berger

Jimmy Kessler

Mark Wood

The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein

Methods and antibodies for treating cancer

The invention relates to a method for the treatment of a disease susceptible to anti-EGFR treatment, comprising the step of administering, to a human being in nee thereof, a combination of an anti-EGFR agent and an anti-neutrophil-chemoattracta agent, wherein said anti-neutrophil-chemoattractant agent is administered in a dosage regimen that is sufficient to reduce one or more undesired dermatological side-effects the anti-EGFR agent. In one embodiment, the anti-EGFR agent is an anti-EGF antibody and the anti-neutrophil-chemoattractant agent is an anti-IL-8 antibody.

Method of treating rash in patients undergoing anti-EGFR therapy

Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.

Functionalized stilbene derivatives as improved vascular targeting agents

Novel quinone and catechol compositions, compositions containing prodrugs of quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. The disclosure particularly relates to the discovery of dual activity agents capable of generating both a vascular targeting effect and direct tumor cell cytotoxicity in order to achieve an enhanced anti-tumor response in a patient.

Compositions and methods with enhanced therapeutic activity

Chrome compounds have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.

Chromene-containing compounds with anti-tubulin and vascular targeting activity

A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.

Tubulin binding ligands and corresponding prodrug constructs

Tubulin binding agents and corresponding prodrug constructs

Growing community of inventors

Klampenborg, Denmark

Klaus Edvardsen